![]() ![]() ![]() One of the keys to a successful AAV workflow is achieving high overall yields of full capsids and efficient removal of empty capsid product impurities. IntroductionĪAV is the main vector for gene therapy and there is a growing need for scalable, cost-efficient, and robust filtration and chromatography-based purification processes. Finally, we found that using Capto™ Q, a single protocol with sodium acetate in the elution buffer, and a step-elution approach greatly improved VG yields and full capsid purity to approximately 80% and above for all the serotypes tested. To further improve full capsid recovery and purity, we will show how Capto™ Q resin with dextran surface extenders, magnesium chloride (MgCl 2), and the elution salt type (especially for rAAV9) significantly enhance separation. ![]() Previously, we have shown how Capto™ Q ImpRes chromatography resin can achieve VG recovery of approximately 60% to 70% and full capsid enrichment to between approximately 40% and 60%. We have developed a protocol for anion exchange with Capto™ Q chromatography resin, which allows near complete separation of full and empty capsids for multiple recombinant serotypes (rAAV2, rAAV5, rAAV8, and rAAV9). This leads to improved viral genome (VG) recovery and a purity of full capsids. Optimizing the polishing step of your AAV process for the separation of full capsids from empty capsids for each serotype is essential. Adeno-associated vector (AAV) is now established as the primary viral vector for gene therapy applications. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |